Clinuvel Pharma jumps as FDA allows phase II study for skin disorder treatment

Clinuvel Pharmaceuticals

20/12/2021 03:33

** Shares of Australian drug developer  CUV.AX  rise as much
as 3.9% to A$27.915, on track for their sharpest single day pct.
rise since Dec. 8 
    ** Co says U.S. Food and Drug Administration has agreed to
the second phase study testing co's drug, Scenesse, as a
monotherapy in patients with skin depigmentation disorder
vitiligo, in a six month clinical trial  urn:newsml:reuters.com:*:nASX4P4fNb
    ** Adds that co has reached an agreement on the clinical
protocol and will commence the study at a specialist hospital
department in the U.S.
    ** Stock up 20.4% this year as of last close vs a 10.8% rise
in the ASX All Ordinaries Index  .AORD  

 (Reporting by Roushni Nair in Bangalore)
 ((Roushni.Nair@thomsonreuters.com))